Rebecca Previs, MD, MS

Dr. Rebecca Previs is a board-certified gynecologic oncologist and the Senior Medical Director at Labcorp Oncology, where she leads the medical affairs team and strategic oncology initiatives to advance precision medicine and improve cancer diagnostics and care delivery. She also serves as an Adjunct Assistant Professor of Obstetrics & Gynecology and Gynecologic Oncology at Duke University Medical Center.

Prior to joining Labcorp, Dr. Previs was an Assistant Professor and principal investigator at Duke, where she led early phase clinical trials translational research focused on biomarkers and the immune microenvironment in gynecologic cancers. Her work has been supported by grant funding from the NIH, Duke WRHR K12 Program, AAGOF-GOG Foundation, and Emerson Collective. She has mentored numerous trainees and served on national advisory committees, including NRG Oncology.

Dr. Previs completed her fellowship in gynecologic oncology at MD Anderson Cancer Center and holds a Master of Science in Cancer Biology. Prior to that, she completed her residency in Obstetrics & Gynecologic at Duke University Medical Center. Her career reflects a deep commitment to advancing women’s health through research, education, and clinical innovation.

https://www.ncbi.nlm.nih.gov/myncbi/1tS7shBBeag5X/bibliography/public/

Areas of Support: Molecular Oncology

Memberships: ASCO; SGO

Board Certifications:

• American Board of Obstetrics and Gynecology, 

Board Certified in Obstetrics and Gynecology: 2018 through present 

Board Certified in Gynecologic Oncology: 2021 through present 

• North Carolina State Medical License – 2009-2013; 2017-present

Notable Roles:

Prior to joining Labcorp as the Director of Medical Affairs, she was an Assistant Professor of Gynecologic Oncology at Duke Cancer Institute and Duke University School of Medicine. As the principal investigator of an externally-funded translational laboratory, her work focused on pre-clinical development of novel cancer therapies and tumor immune microenvironment. 

Upon completion of her training, Dr. Previs joined the Division of Gynecologic Oncology at Duke University, where she operated on patients with newly diagnosed or suspected gynecologic cancers. Her clinical practice focused enrolling patients with recurrent cancer on early phase and immuno-oncology clinical trials. Becca maintains an adjunct faculty appointment at Duke within the Department of Obstetrics & Gynecology, Division of Gynecologic Oncology in Durham, North Carolina. 

 

Education:

• Fellowship, Gynecologic Oncology - The University of Texas MD Anderson Cancer Center
• Master of Science - The University of Texas, Graduate School of Biomedical Sciences, Cancer Biology
• Resident, Obstetrics and Gynecology - Duke University Medical Center
• MD - University of Virginia
• BS, BA - University of Richmond, Majored in Chemistry and Rhetoric and Communications; Minored in Biology and Women’s Studies

Publications:

• Jun 07, 2025 Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage
• May 31, 2025 Unveiling the differences in tumor immune microenvironment between KRAS-wildtype and KRAS-mutant pancreatic ductal adenocarcinoma
• Nov 23, 2024 Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers
• Oct 30, 2024 Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer - a case series of divergent results from a large reference laboratory
• Oct 29, 2024 A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
• Apr 29, 2024 Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer
• Apr 07, 2024 Landscape of HIF-1-alpha expression across 24,186 solid tumors using comprehensive immune profiling
• Apr 07, 2024 Landscape of TIGIT and PD-L1 co-expression in solid tumors
• Mar 19, 2024 The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
• Feb 12, 2024 Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
• Jan 30, 2024 LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes
• Dec 11, 2023 Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort
• Dec 11, 2023 Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer
• Nov 17, 2023 Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response
• Nov 17, 2023 Genomic stability of prostate cancers with homologous recombination gene alterations
• Nov 17, 2023 Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy
• Nov 17, 2023 Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making
• Nov 17, 2023 A Consensus-Based Machine Learning Framework to Determine Genetically Inferred Ancestry (GIA) from Comprehensive Genomic Profiling (CGP) Sequencing Results
• Nov 14, 2023 Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
• Nov 04, 2023 Distinct immunotherapy immune response phenotypes in non-small cell lung cancer present with unique genomic alteration profiles
• Nov 03, 2023 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers
• Nov 03, 2023 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
• Nov 03, 2023 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
• Nov 03, 2023 Immune microenvironment of primary versus metastatic melanoma of the brain
• Nov 03, 2023 Metastatic triple negative breast cancer has distinct tumor immune landscape
• Nov 01, 2023 Comprehensive Genomic and Immune Profiling of Early-Onset Colorectal Cancer
• Oct 05, 2023 Healthcare access dimensions and uterine cancer survival: A National Cancer Database study
• Sep 29, 2023 PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
• Sep 15, 2023 Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
• Jun 04, 2023 Comparison of immune microenvironment between primary and metastatic breast tumors
• Jun 01, 2023 Evolving landscape of HER2-low breast cancer: New diagnosis and treatment paradigm shift
• May 08, 2023 RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers
• Apr 14, 2023 Validation of the Labcorp Plasma Focus test to facilitate precision oncology through cell-free DNA genomic profiling of solid tumors
• Feb 14, 2024 Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer